Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus

NCT03254849 is registered in ClinicalTrials.gov with Profil Institut für Stoffwechselforschung GmbH as lead sponsor.

NCT NCT03254849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03254849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Profil Institut für Stoffwechselforschung GmbH
Phase
Phase 4
Overall status
Completed
Start date
December 8, 2017
Completion date
April 20, 2020
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus